Highlights Newsletter 4 This newsletter presents you the following key sessions: Watch the VIDEOINTERVIEW with Prof. Ruth O’Ryan on the BELLE study: a Phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment At home administration of trastuzumab subcutaneous has a safety profile comparable with prior studies and is positively assessed by patients and healthcare professionals A sentinel lymph node biopsy is feasible and safe for patients treated with neoadjuvant chemotherapy for a large breast tumour and no clinical signs of the cancer in the axillary lymph nodes BROCADE study: adding the PARP inhibitor veliparib to chemotherapy significantly improves overall response rate in BRCA mutant breast cancer Chemotherapy does not boost ageing progression in elderly breast cancer patients Fulvestrant most effective in patients without visceral metastases